Key result
Valsalva phase 2 DBP rise ≥ 15 mmHg identifies hyperadrenergic POTS patients.
Why the study?
Muscle sympathetic nerve activity is valuable for managing POTS but microneurography is clinically impractical, prompting evaluation of the Valsalva phase 2 diastolic blood pressure rise as a sympathetic marker.
Does the Valsalva phase 2 diastolic blood pressure rise (DBPVM2l_rise) serve as a sympathetic marker to identify hyperadrenergic POTS?
Cross-Sectional (n=43)
No
Does the Valsalva phase 2 diastolic blood pressure rise (DBPVM2l_rise) serve as a sympathetic marker to identify hyperadrenergic POTS?
A Valsalva phase 2 diastolic blood pressure rise ≥ 15 mmHg serves as a practical, non-invasive clinical marker to identify hyperadrenergic POTS driven by augmented neurovascular transduction.
Answers are grounded in this paper and cite their sources.
May support non-invasive hyperadrenergic POTS phenotyping; hypothesis-generating pending prospective validation.
Purpose Muscle sympathetic nerve activity (MSNA) is valuable for managing postural tachycardia syndrome (POTS), but microneurography is clinically impractical. We investigated whether the Valsalva phase 2 diastolic blood pressure rise (DBP VM2l_rise ) serves as a sympathetic marker and proposed enhanced neurovascular transduction as a pathophysiological mechanism in hyperadrenergic POTS. Methods We included 21 POTS women and 22 healthy women to perform Valsalva and microneurography. MSNA spike rate was obtained using stationary wavelet transformation. The DBP VM2l_rise cut point for hyperadrenergic POTS was optimized by the golden section search with its correlation to phase 2 MSNA spike rate as an objective function. We defined peripheral sympathetic neurovascular transduction (psNVT) as a ratio of DBP VM2l_rise to early phase 2 MSNA increase. We compared Valsalva responses between the identified hyperadrenergic and non-hyperadrenergic POTS. Results The DBP VM2l_rise strongly correlated with the Valsalva phase 2 MSNA spike rate percentage change from baseline in healthy ( r = 0.874, p < 0.001). The DBP VM2l_rise cutoff criterion of 15 mmHg optimally separated POTS into 7 hyperadrenergic (≥ 15 mmHg, r = 0.902, p = 0.014) and 14 non-hyperadrenergic (< 15 mmHg, r = 0.629, p = 0.021). Although similar MSNA spike rate, the hyperadrenergic group had higher baseline systolic blood pressure (118 ± 10 vs 105 ± 12 mmHg, p = 0.026), shorter pressure recovery time (1.15 ± 0.75 vs 2.59 ± 1.17 s, p = 0.048), and higher psNVT (2.60 ± 1.02 vs 0.58 ± 0.46 mmHg/spike·s −1 , p < 0.001) than the non-hyperadrenergic POTS. Conclusion DBP VM2l_rise ≥ 15 mmHg could be a sympathetic clinical marker and could identify hyperadrenergic POTS, characterized by enhanced neurovascular transduction despite comparable MSNA levels. This novel pathophysiological insight underscores the importance of sympathetic markers in POTS clinical management.
No takes yet. Share an insight, caveat, or question.
Kulapatana et al. (2026) conducted a cross-sectional in Postural tachycardia syndrome (POTS) (n=43). Late phase 2 diastolic blood pressure rise (DBPVM2l_rise) ≥ 15 mmHg vs. DBPVM2l_rise < 15 mmHg was evaluated on Peripheral sympathetic neurovascular transduction (psNVT) (95% CI 1.155-2.867, p=<0.001). A late phase 2 diastolic blood pressure rise of ≥15 mmHg during the Valsalva maneuver identified hyperadrenergic POTS patients, who exhibited higher peripheral sympathetic neurovascular transduction compared to non-hyperadrenergic patients.
Synapse has enriched 10 related papers. Consider them for comparative context: